Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells' Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway
Sign Up to like & getrecommendations! Published in 2022 at "Canadian Respiratory Journal"
DOI: 10.1155/2022/8433960
Abstract: Dexmedetomidine (DEX), which is reported to be a newly discovered, novel α-2 adrenoceptor agonist, is known to exhibit anti-inflammatory properties in several diseases. DEX regulates inflammation-related signaling pathways and genes through interactions with several miRNAs.… read more here.
Keywords: mir 140; jnk bnip3; expression; dex ... See more keywords